If you're in your late thirties or forties and noticing that sleep no longer does what it used to — you wake feeling unrefreshed, recovery is slower, and afternoon fatigue has become routine — you're not imagining it. These changes are common and have a well-understood physiological basis.
Growth hormone (GH) plays a central role in how the body restores itself during sleep. As we age, GH secretion naturally declines — and with it, the sleep architecture that depends on it. There is growing interest in GP-prescribed peptide therapy as one approach to supporting natural GH signalling in adults navigating these changes.
Two peptides that come up frequently in this context are CJC-1295 and Ipamorelin. This article provides an educational overview of how they work, who might be considered a candidate, and how they are legally accessed in Australia.
What Are CJC-1295 and Ipamorelin?
CJC-1295 and Ipamorelin are two distinct peptides that are often prescribed together because they act through complementary mechanisms to support the body's own GH production.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It signals the pituitary gland to produce and release GH in a pulsatile pattern — the same rhythm the body uses naturally. Rather than bypassing the system, it works with it.
Ipamorelin acts via the ghrelin receptor as a GH secretagogue. Importantly, it does not appear to significantly elevate cortisol or prolactin levels, which is why it is a commonly preferred option in GP-supervised protocols used to support natural GH signalling.
When prescribed together as a compounded combination, the two peptides may act through complementary pituitary pathways, supporting a more robust GH pulse than either might produce alone. Suitability is always determined by a GP following individual assessment.
If you're weighing up different peptide options, our article on BPC-157 vs CJC-1295 provides a useful comparison.
How They Differ From Growth Hormone Injections
A common question is whether CJC-1295 and Ipamorelin are the same as synthetic human growth hormone (HGH) injections. They are not.
Synthetic HGH directly introduces exogenous growth hormone into the body. CJC-1295 and Ipamorelin work upstream — they signal the pituitary to produce GH naturally, with the body's own feedback mechanisms remaining active. Your GP will assess which approach, if any, is appropriate for your circumstances.
Why Sleep Quality Declines With Age — And What GH Has to Do With It
Growth hormone is predominantly secreted during slow-wave sleep (SWS) — the deepest phase of the sleep cycle, associated with physical restoration, immune function, and metabolic regulation. In younger adults, GH pulses during this phase are robust and well-coordinated.
With age, time spent in slow-wave sleep decreases and GH pulsatility naturally declines. Reduced GH may contribute to lighter, less restorative sleep — and lighter sleep may in turn reduce GH secretion. The result is the kind of unrefreshing sleep many adults over 35 describe: hours in bed, but waking without genuine restoration.
This physiological connection is why GH-related peptide therapy has been explored in clinical contexts alongside broader approaches to supporting sleep quality and daytime energy. Peptide therapy is not a treatment for insomnia or any sleep disorder. Individual suitability must be assessed by a GP.
Who Might Be a Candidate?
The adults who tend to discuss CJC-1295 and Ipamorelin with their GPs typically:
- Are aged 35 and over with age-related changes in sleep quality and energy
- Experience slower recovery from physical activity than in previous years
- Have had other contributing factors (such as sleep apnoea or thyroid dysfunction) appropriately investigated
- Are not pregnant or breastfeeding
- Have no active or suspected malignancy
This is not a definitive eligibility list. Candidacy is determined entirely by your GP following a clinical consultation, which typically includes bloodwork such as IGF-1 levels and a thorough medical history review.
For detail on the prescription process, see our guide on how to get peptides prescribed in Australia.
How Is It Prescribed in Australia?
CJC-1295 and Ipamorelin are Schedule 4 prescription medicines — they cannot be purchased over the counter or legally obtained without a valid GP prescription. When prescribed, they are dispensed by a TGA-licensed compounding pharmacy as a compounded off-label preparation.
High Performance Human (HPH) operates this pathway via telehealth, making it accessible to Australians in all states and territories. See our article on GP-prescribed vs grey market peptides before considering any unregulated online supplier.
What Does the Prescription Process Look Like?
The process at HPH follows a clear structure:
Online Assessment
A health questionnaire covering your medical history and current symptoms.
GP Consultation
A telehealth appointment to review your history and discuss your circumstances.
Bloodwork
Pathology such as IGF-1 arranged if the GP determines it is required.
Prescription
A compounded preparation prescribed if clinically appropriate.
Ongoing Supervision
Follow-up consultations to monitor your protocol.
No specific outcomes are promised at any stage. The GP's role is to assess, prescribe where appropriate, and supervise your protocol safely.
Important Considerations and Safety
CJC-1295 and Ipamorelin are not appropriate for individuals with active or suspected malignancy, pregnancy, breastfeeding, or untreated pituitary, thyroid, or adrenal conditions. Your GP will assess all relevant contraindications during consultation.
Side effects are generally reported as mild under medical supervision and may include transient injection site reactions, water retention, or mild fatigue.
Competitive athletes: Both peptides are prohibited under the World Anti-Doping Agency (WADA) code. If you compete in a WADA-governed sport, these substances are not permitted.
For a broader safety overview, see are peptides safe?
Frequently Asked Questions
Is CJC-1295 and Ipamorelin legal in Australia?
Yes — with a valid GP prescription. Both are Schedule 4 substances, legal to possess and use when prescribed by a registered medical practitioner.
Do I need blood tests before starting?
Typically yes. The specific pathology required is determined by your GP at consultation. IGF-1 levels are commonly assessed to establish a baseline.
Can I access this via telehealth?
Yes. HPH provides telehealth GP consultations to Australians nationwide. The full process — assessment, prescription, and follow-up — can be completed remotely.
Take the First Step
CJC-1295 and Ipamorelin are an area of genuine clinical interest for adults experiencing age-related changes in sleep, energy, and recovery. Like all medical interventions, they are not appropriate for everyone — suitability requires a proper GP assessment.
The first step is an online assessment with one of our GPs. Start your HPH assessment here — no referral required, available Australia-wide.
This article is for informational purposes only and does not constitute medical advice. Peptide therapy must be prescribed by a registered Australian GP following a clinical assessment. Results may vary.